Baloxavir: First Global Approval

Drugs

Volumn 78, Issue 6, 2018, Pages 693-697

  Heo, Young A ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BALOXAVIR; ANTIVIRUS AGENT; MESSENGER RNA; OXAZINE DERIVATIVE; PYRIDINE DERIVATIVE; THIEPIN DERIVATIVE; TRIAZINE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; HEADACHE; HUMAN; INFLUENZA A; INFLUENZA B; NONHUMAN; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; ADOLESCENT; ADULT; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CHILD; INFLUENZA; INFLUENZA A VIRUS; INFLUENZA B VIRUS; JAPAN; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; DRUG APPROVAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; JAPAN; MIDDLE AGED; OXAZINES; PYRIDINES; RNA, MESSENGER; THIEPINS; TRIAZINES; YOUNG ADULT;

EID: 85045076594     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-018-0899-1     Document Type: Article

References (15)

1. Ferguson NM, Cummings DA, Fraser C, et al. Strategies for mitigating an influenza pandemic. Nature. 2006;442(7101):448–52.
2. Koszalka P, Tilmanis D, Hurt AC. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses. 2017;11(3):240–6.
3. TM (baloxavir): Japanese prescribing information 2018. http://www.pmda.go.jp/. Accessed 26 Feb 2018.
4. TM (baloxavir marboxil) tablets 10 mg/20 mg approved for the treatment of influenza types A and B in Japan [media release]. 23 Feb 2018.
5. Shionogi & Co. Ltd. Shionogi enters into a license and collaboration agreement with Roche for its anti-flu drug, S-033188 [media release]. 29 Feb 2016.
6. Watanabe A, Hirotsu N, Ishida T, et al. Pharmacokinetic/pharmacodynamic analysis of S-033188, an influenza cap-dependent endonuclease inhibitor, from a phase 2, randomized, double-blind, placebo controlled study in otherwise healthy adults with seasonal influenza [abstract no. OS0752 and oral presentation]. In: 27th European congress of clinical microbiology and infectious diseases (ECCMID). 2017.
7. Taniguchi K, Kobayash M, Ando Y, et al. Inhibitory effect of S-033188/S-033447, a novel inhibitor of influenza virus cap-dependent endonuclease, against highly pathogenic avian influenza virus A/H5N1 [abstract no. P1974 and poster]. In: 27th European congress of clinical microbiology and infectious diseases (ECCMID). 2017.
8. Kitano M, Yamamoto A, Noshi T, et al. Synergistic antiviral activity of S-033188/S-033447, a novel inhibitor of influenza virus cap-dependent endonuclease, in combination with neuraminidase inhibitors in vitro [abstract no. 1214]. Open Forum Infect Dis. 2017;4(Suppl 1):S371.
9. Fukao K, Ando Y, Noshi T, et al. One-day oral dosing of S-033188, a novel inhibitor of influenza virus cap-dependent endonuclease, exhibited significant reduction of viral titre and prolonged survival in mice infected with influenza B virus [abstract no. 2175 and poster]. In: 27th European congress of clinical microbiology and infectious diseases (ECCMID). 2017.
10. Fukao K, Ando Y, Noshi T, et al. Delayed dosing of S-033188, a novel inhibitor of influenza virus cap-dependent endonuclease, exhibited significant reduction of viral titer and mortality in mice infected with influenza A virus [abstract no. 1514]. Open Forum Infect Dis. 2017;4(Suppl 1):S473.
11. Kawasaki A, Sato C, Ishibashi T. A phase 1 study of safety, tolerability and pharmacokinetics of oral single-dose S-033188, a novel anti-influenza agent, in healthy adult male subjects [abstract no. 2238 and poster]. Open Forum Infect Dis. 2016;3(Suppl 1):S599.
12. Portsmouth S, Kawaguchi K, Arai M, et al. Cap-dependent endonuclease inhibitor S-033188 for the treatment of influenza: results from a phase 3, randomized, double-blind, placebo- and active-controlled study in otherwise healthy adolescents and adults with seasonal influenza [abstract no. LB-2]. Open Forum Infect Dis. 2017;4(Suppl 1):S734.
13. Shionogi & Co. Ltd. Shionogi to present S-033188 phase 3 CAPSTONE-1 study results for treatment of influenza at IDWeek 2017 [media release]. 5 Oct 2017.
14. US National Institutes of Health. ClinicalTrials.gov [identifier NCT02949011]. 2018. https://www.clinicaltrials.gov/. Accessed 05 Mar 2018.
15. Japan Pharmaceutical Information Center. Clinical trials informations [identifier JapicCTI-173811]. 2018. http://www.clinicaltrials.jp/. Accessed 05 Mar 2018.